文献速递类风湿关节炎自身炎症与 IgG4 相关病

儿童风湿病托珠单抗治疗严重不良事件的真实世界研究

Serious adverse events in children with juvenile idiopathic arthritis and other rheumatic diseases on tocilizumab - a real-world experience.
PubMed 文献 · Semin Arthritis Rheum · 2020-05-30

发生严重不良事件者发病及用药年龄更小,输注反应者更多为全身型JIA或其他自身炎症病且疾病活动。

要点

  • 托珠单抗治疗儿童风湿病严重不良事件发生率15.3/100患者年,四分之一患儿受累。
  • 严重不良事件以感染和输注反应为主,输注反应与持续活动的自身炎症病相关。
  • 发生严重不良事件者发病及托珠单抗起始年龄显著更小。

核心结论

  • 该队列中四分之一儿童发生严重不良事件,最常见为严重感染。
  • 严重输注反应与持续活动的自身炎症性疾病相关。
  • 需对托珠单抗治疗患儿、尤其年幼且全身炎症明显者持续仔细监测。

研究设计与样本

  • 法国两个三级儿童风湿中心2007年1月至2019年6月的回顾性研究。

主要发现

  • 全身型JIA 43例、多关节型JIA 43例,托珠单抗起始中位年龄8.9岁(IQR 4.7–12.1)。
  • 81%患儿既往使用泼尼松、84%既往使用生物制剂,托珠单抗中位疗程1.6年(IQR 0.5–2.7),总暴露215患者年。
  • 发生严重不良事件者发病年龄(p=0.034)和托珠单抗起始年龄(p=0.016)显著更小。
  • 发生输注反应者更可能为全身型JIA或其他自身炎症病(p=0.021),且均有活动性疾病;末次随访61例(59%)仍在用托珠单抗。

关键数值与推荐

  • 严重不良事件定义为危及生命和/或需住院、导致永久残疾或停药的事件。

临床怎么用

  • 对托珠单抗治疗的儿童风湿病患者应持续仔细监测严重不良事件。
  • 年幼且全身炎症明显者应作为重点监测对象。
  • 出现输注反应时应评估自身炎症性疾病是否持续活动。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the incidence rate and type of serious adverse events (SAE) in children with rheumatic inflammatory diseases treated with the interleukin 6 blocker tocilizumab (TCZ). METHODS: A retrospective review of all consecutive patients diagnosed with an inflammatory rheumatic disease and receiving at least one dose of TCZ was performed in two French tertiary pediatric rheumatology centers between 01/2007 and 06/2019. SAE were defined as a life-threatening event and/or an event requiring hospital admission, leading to permanent disability or treatment discontinuation. RESULTS: One hundred four children (64 female) were included. Most children suffered from systemic (n = 43) or polyarticular-course juvenile idiopathic arthritis (n = 43). Median age at TCZ start was 8.9 years (IQR 4.7 - 12.1), most children had received prednisone (81%), and/or a biologic agent (84%) prior to TCZ. Median TCZ treatment duration was 1.6 years (IQR 0.5 - 2.7), total TCZ exposure 215 patient years. Thirty-three SAE were observed in 26 (25%) children (SAE 15.3/100 patient years), mostly infections and infusion reactions. Children with SAE were significantly younger at disease onset (p = 0.034) and TCZ initiation (p = 0.016). Children experiencing infusion reactions were more likely to have systemic JIA or another autoinflammatory disease (p = 0.021), they all had active disease. At last follow up, 61 (59%) children remained on TCZ. CONCLUSION: In this cohort, SAE and most commonly serious infections were observed in a quarter of children. Severe infusion reactions were associated with persistently active autoinflammatory disease. Ongoing careful monitoring of TCZ-treated patients, especially young children with marked systemic inflammation is required.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Aeschlimann FA, Dumaine C, Wörner A, et al. Serious adverse events in children with juvenile idiopathic arthritis and other rheumatic diseases on tocilizumab - a real-world experience. Semin Arthritis Rheum. 2020. PMID: 32526594. doi:10.1016/j.semarthrit.2020.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。